Ad
CELG - Celgene Corporation Stock Trading
About | Celgene Corporation (NASDAQ:CELG)
Not available
Quote | Celgene Corporation (NASDAQ:CELG)
| Last: | $ |
|---|---|
| Change Percent: | 0.88% |
| Open: | $101.11 |
| Close: | $101.86 |
| High: | $102.02 |
| Low: | $101.11 |
| Volume: | 2,053,419 |
| Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Celgene Corporation (NASDAQ:CELG)
-
In this clip from "The Pharma & Biotech Show" on Motley Fool Live , recorded on Feb. 2 , Motley Fool contributor Brian Orelli analyzes Gilead 's (NASDAQ: GILD) earnings report and discusses why the biotech giant could see fairly low revenue growth or even see earnings dr...
-
Bristol Myers Squibb has an impressive portfolio of assets and strong financials. The company has recently wrapped up large acquisitions. The company is focused on redeveloping its portfolio and expects a massive increase in revenue from new businesses. Going forward, we expect sh...
Message Board Posts | Celgene Corporation (NASDAQ:CELG)
| Subject | By | Source | When |
|---|---|---|---|
| Better Buy: Celgene vs. Gilead Sciences | BottomBounce | investorshub | 10/24/2020 12:38:18 PM |
| Sorry, dont know | patrickjishere | investorshub | 02/18/2019 10:31:14 PM |
| Do you or anyone here know the tax | rosemountbomber | investorshub | 02/18/2019 10:08:04 PM |
| Advances in Cancer Drugs Fuel Deal -- WSJ | TheFinalCD | investorshub | 01/04/2019 2:09:31 PM |
| Yep, I like $BMY and the deal. | patrickjishere | investorshub | 01/03/2019 7:24:29 PM |
News, Short Squeeze, Breakout and More Instantly...
Ad
-
In this clip from "The Pharma & Biotech Show" on Motley Fool Live , recorded on Feb. 2 , Motley Fool contributor Brian Orelli analyzes Gilead 's (NASDAQ: GILD) earnings report and discusses why the biotech giant could see fairly low revenue growth or even see earnings dr...
-
What coronavirus? Amgen 's (NASDAQ: AMGN) latest set of quarterly figures, delivered Tuesday, showed growth in the company's fundamentals during a challenging time for companies across all economic sectors. The veteran biotech company booked revenue of nearly $6.21 billion in the second qu...
-
It's scary out there right now for investors, with wild market swings and a lot of negative news coming out of quarterly reports. There is one sector, however, that will survive and likely thrive despite the coronavirus pandemic shutdown -- healthcare. That said, investors shouldn't head for jus...